Business Description
Celyad Oncology SA
ISIN : BE0974260896
Compare
Compare
Traded in other countries / regions
CYAD.Belgium1C0.Germany0QFK.UKCYADY.USA IPO Date
2013-07-10Description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates majority of its revenue from Cardiology segment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.28 | |||||
| Equity-to-Asset | 0.08 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 27.1 | |||||
| 3-Year FCF Growth Rate | 18.5 | |||||
| 3-Year Book Growth Rate | -61.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 0.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.5 | |||||
| Shareholder Yield % | 15.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -117.18 | |||||
| ROA % | -44.37 | |||||
| ROIC % | -71.91 | |||||
| ROC (Joel Greenblatt) % | -1041.55 | |||||
| ROCE % | -62.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.54 | |||||
| Price-to-Tangible-Book | 17.04 | |||||
| EV-to-EBIT | -0.68 | |||||
| EV-to-EBITDA | -0.68 | |||||
| EV-to-FCF | -0.34 | |||||
| Earnings Yield (Greenblatt) % | -147.78 | |||||
| FCF Yield % | -202.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celyad Oncology SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.62 | ||
| Beta | -0.07 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 3.92 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 3.92 - 3.92 | ||
| Shares Outstanding (Mil) | 41.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celyad Oncology SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celyad Oncology SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celyad Oncology SA Frequently Asked Questions
What is Celyad Oncology SA(LTS:0QFK)'s stock price today?
The current price of LTS:0QFK is €3.92. The 52 week high of LTS:0QFK is €3.92 and 52 week low is €3.92.
When is next earnings date of Celyad Oncology SA(LTS:0QFK)?
The next earnings date of Celyad Oncology SA(LTS:0QFK) is 2024-08-02 Est..
Does Celyad Oncology SA(LTS:0QFK) pay dividends? If so, how much?
Celyad Oncology SA(LTS:0QFK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers